Search clinical trials for: Feiba VH

Total 38 results

Novo Nordisk A/S

Completed

Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IX (DOSE)

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

United States
Novo Nordisk A/S

Completed

Trial of NovoSeven® in Haemophilia - Joint Bleeds

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

United States
Rush University Medical Center
Advocate Health Care

Completed

Fixed-dose Activated Versus Variable-dose Inactivated Prothrombin Complex Concentrate for Warfarin-associated Major Bleed

Hemorrhage
Rambam Health Care Campus

Unknown

0050-19-RMB CTIL - VNOTES Compared to VH for Vaginal Apex Prolapse

Vaginal Prolapse
Ain Shams University

Completed

Laparoscopic vs Vaginal Hysterectomy for Benign Gynaecological Disease

Benign Gynecological Disease

Egypt
Piedmont Healthcare

Completed

Validation of Stenosis Assessment by Coronary Artery Computed Tomography Against Invasive Measurements of Fractional Flow Reserve in Patients With Significant Coronary Artery Stenoses

Coronary Artery Stenosis

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Terminated

Fibrin Sealant in Preventing Fluid Build Up During Surgery in Patients Undergoing Breast Reconstruction

Breast Cancer | Perioperative/Postoperative Complications

United States
University of Pittsburgh
The University of Hong Kong

Completed

Prevention and Treatment of Voice Problems in Teachers (Prevention)

Voice Disorder

United States
Children's Hospital Los Angeles
Takeda

Active, not recruiting

A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab

Hemophilia A With Inhibitor

United States
Mayo Clinic

Withdrawn

FEIBA to Optimize Postcardiopulmonary Bypass Hemostasis in Pediatric Cardiac Patients

Cardiac Disease
Skane University Hospital

Completed

The FEIBA NovoSeven Comparative Study

Severe Hemophilia A With an Inhibitor

Sweden
Sheba Medical Center

Completed

Combination Therapy of Low Doses of rFVIIa and FEIBA for Severe Hemophilia A Patients With an Inhibitor to Factor VIII

Hemophilia A
Baxter Healthcare Corporation

Completed

Efficacy and Safety of Fibrin Sealant Vapor Heated Solvent/Detergent Treated (FS VH S/D) for Reduction of Lymphatic Leakage by Sealing Axillary Lymph Node Dissection Sites

Breast Cancer | Lumpectomy | Mastectomy Plus Axillary Lymph Node Dissection | Lymphatic Leakage

Germany, Austria, France, Italy
Baxter Healthcare Corporation

Completed

Safety and Hemostatic Efficacy of Fibrin Sealant Vapor Heated, Solvent/Detergent Treated (FS VH S/D) Compared With Currently Licensed TISSEEL VH Fibrin Sealant in Subjects Undergoing Cardiac Surgery

Cardiopulmonary Bypass | Sternotomy | Cardiac Surgery Requiring Cardiopulmonary Bypass and Median Sternotomy

United States
Seed Health

Active, not recruiting

Randomized, Double-Blind Placebo-Controlled Trial to Assess Overall User Experience of a Synbiotic Vaginal Suppository

Vaginal Personal Care

United States
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

FEIBA Reconstitution Volume Reduction and Faster Infusion Study (FEIBA STAR)

Hemophilia A or B With Inhibitors

Croatia, North Macedonia, Ukraine
Tulane University School of Medicine

Completed

Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors (ProFEIBA)

Hemophilia A With Inhibitors

United States
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé Et de la Recherche Médicale, France

Completed

Imaging and Biomarkers of Atherosclerosis in Patients With Stable or Unstable Coronary Artery Disease (BIOCORE-2)

Coronary Artery Disease | Atherosclerosis | Acute Coronary Syndrome

France
Volcano Corporation

Completed

Vascular Evaluation for Revascularization: Defining the Indications for Coronary Therapy: A Pilot Study (VERDICT)

Coronary Artery Disease
Baxter Healthcare Corporation

Completed

Efficacy and Safety of FS VH S/D 4 S-apr for Flap Adherence in Rhytidectomy

Face-lift | Facial Rhytidectomy

United States
Baxter Healthcare Corporation

Completed

Fibrin Sealant Vascular Surgery Study

Adjunct to Hemostasis in Vascular Surgery (Synthetic Vascular Grafts)

United States
Oregon Health and Science University

Completed

FEIBA and Use of Blood Products in Cardiac Surgery (FEIBA)

Cardiovascular Disease

United States
Baxter Healthcare Corporation

Completed

Safety and Efficacy Study of FS 4 IU VH S/D (Fibrin Sealant With 4IU/mL Thrombin, Vapor Heated, Solvent/Detergent Treated) to Adhere Split Thickness Skin Grafts and Improve Wound Healing in Burn Patients

Deep Partial or Full Thickness Wounds

United States
Baxalta now part of Shire

Completed

Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor

Hemophilia A | Hemophilia B | Hemophilia A or B With Inhibitors

Poland, United States, Bulgaria, Romania, Japan, Russian Federation, New Zealand, Croatia, Ukraine, Brazil
Oslo University Hospital

Completed

A Comparison Study of Bypassing Agent Therapy With and Without Tranexamic Acid in Haemophilia A Patients With Inhibitor (BPATXAS)

Hereditary Factor VIII Deficiency Disease With Inhibitor

Norway
Baxter Healthcare Corporation

Completed

Efficacy and Safety of FS VH S/D 500 S-apr (Tisseel) as an Adjunct to Sutured Dural Repair in Cranial Surgery

Cerebrospinal Fluid Leak

United States, Germany, Spain, Czechia
Emory University
Takeda Pharmaceuticals North America, Inc.

Recruiting

SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis (SAFE)

Hemophilia A

United States
Emory University
Octapharma

Recruiting

Treatment of Hemophilia A Patients With FVIII Inhibitors (MOTIVATE)

Hemophilia A

United States, Germany
Sunway University

Not yet recruiting

Reducing Vaccine Hesitancy (VH) And Vaccine Refusal (VR): Its' Correlation Factors and an Educational Intervention Programme

COVID-19 Vaccination

Malaysia
Baxter Healthcare Corporation
Baxter Innovations GmbH

Completed

Fibrin Sealant VH S/D 500 S-apr in Hepatic Resection

Bleeding (Oozing) in Hepatic Resection

Germany
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors (HAVEN 1)

Hemophilia A

Korea, Republic of, United States, France, Germany, Italy, South Africa, Spain, Japan, United Kingdom, Poland, Taiwan, Australia, Costa Rica, New Zealand
Hobart Harris

Withdrawn

A Study of Fibrin Sealant Plus Silver Microparticles to Prevent Incisional Hernias Following Abdominal Surgery (HiP_1)

Hernia | Ventral Hernia | Abdominal Hernia
University of South Florida
Dynatherm Medical Inc.

Completed

Intraoperative Warming Comparison of Devices

Hypothermia

United States
Baxter Healthcare Corporation

Completed

Efficacy and Safety of ARTISS for Flap Adherence in Abdominoplasty

Hematoma | Seroma

United States
Baxter Healthcare Corporation

Completed

Fibrin Sealant for the Sealing of Dura Sutures

Dura Defects | Pathological Processes in the Posterior Fossa

United States, Canada
Celtic Pharma Development Services
Neurobiological Technologies

Completed

XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors

Brain Tumor | Brain Edema

United States, Canada
Baxter Healthcare Corporation

Completed

Efficacy and Safety Study of Fibrin Sealant With 4 IU/mL Thrombin, Vapor Heated, Solvent Detergent Treated (FS VH S/D 4) in Face-Lift Procedures

Facial Rhytidectomy (Face-lift)

United States
Baxter Healthcare Corporation

Completed

FS VH S/D 500 S-apr in Vascular Surgery

Hemostasis in Participants Receiving Peripheral Vascular Expanded Polytetrafluoroethylene (ePTFE) Graft Prostheses

United States

Search clinical trials for: Feiba VH

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations